THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Vangelis Vergetis, Executive DirectorTo achieve this feat, Intelligencia has developed a cloud-based AI platform that focuses on assessing the risk of clinical trials and interpreting the multitude of factors that contribute to the risk. “For AI to succeed in this space, it needs to do much better than being a black box that spits out a number,” says Dimitrios Skaltsas, Executive Director of Intelligencia. He continues: “This is why we’ve trained models that not only assess the risk but provide full transparency behind the most important risk factors.” This platform offers a suite of functionalities that provide data clarity and ML-fueled predictions to enable critical decision making within the pre-clinical and clinical space.
Backed by a robust interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers, Intelligencia is capable of bringing together and interpreting disparate data across the life sciences industry. In addition, the company has also extensively curated proprietary data sets that power its predictive models. “AI is only as good as the data that power it. This is why we’ve been very particular in making sure that our platform includes both a large amount of relevant data, but also high-quality data.
Dimitrios Skaltsas, Executive Director
You don’t want to be in a ‘garbage in garbage out’ situation,” says Skaltsas.
Our ultimate objective is to change how pharma and biotech companies think about the risks of drug development, and how they can make choices differently using ML
As an implementation highlight, a particular client was investigating a promising drug for breast cancer. They had almost completed an initial clinical trial (Phase 1), but a few questions held them back from continuing to Phase 2. For instance, how does our program compare to other similar drugs in development? To what degree should we prioritize this program versus others in our portfolio? Working with Intelligencia, the company gained confidence in the quality of their program versus the competition and was also able to make select changes to their program and Phase 2 trial that increased the drug’s chances of approval by more than 40%.
In a world where diseases will impact nearly every individual, Intelligencia works to make a difference. “Although we have some of the top ten or twenty pharma and biotech companies in the world working with us, we continuously seek for more spread and acceptance,” concludes Skaltsas.
Company
Intelligencia.ai
Management
Vangelis Vergetis, Executive Director and Dimitrios Skaltsas, Executive Director
Description
Backed by a robust interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers, Intelligencia leverages a proprietary methodology to deliver its solution to the researchers. This platform pulls information from hundreds of characteristics that are fed into various algorithms to pick up trends in order to answer the questions of drug developers. Whether it be to assist in prioritization of pre-clinical assets to take forward to the clinic, help to make critical go/no-go decisions on development or to evaluate potential compounds to in-license, Intelligencia provides an objective outside view deemed valuable by pharma and biotech today
NEW YORK- Leading healthcare technology company Intelligencia AI™ recently appointed pharmaceutical industry leader Névine Zariffa as its Scientific Advisory Board Chair. Formalizing the Scientific Advisory Board demonstrates the company’s investment in growth and signals the next chapter of maturity for the 2017 New York-founded company.
With its deeply curated scientific data assets and artificial intelligence (AI) algorithms, Intelligencia AI is transforming the biopharmaceutical industry's approach to assess the probability of technical and regulatory success (PTRS) of drugs in development to drive more efficient clinical development and business decisions.
In her new role, Ms. Zariffa will provide strategic guidance on the company’s product development roadmap while leading and coordinating the activities of the other accomplished leaders of the Scientific Advisory Board.
“Ms. Zariffa’s deep clinical development expertise coupled with her inquisitive approach towards industry needs and innovation make her the ideal candidate for this new role. She’s been a trusted advisor since 2021 and will continue to support our growth,” stated CEO and Co-founder, Dimitrios Skaltsas.
With her 25-year career in the pharmaceutical industry in the fields of biostatistics and data science, Ms. Zariffa brings extensive experience across all phases of drug development to Intelligencia AI. Most recently she served as the Senior Vice President of Biometrics and Information Sciences at AstraZeneca (AZ) where she was a core member of Governance and guided executives on R&D investment decisions. While at AZ, she also led its Enterprise Data and Analytics Program. During her career, she has made critical contributions to the development of over 200 drug projects across various therapeutic areas. Ms. Zariffa currently serves as a strategic advisor to select clients and continues to shape large data-oriented scientific consortia.
“I’m honored to lead the very accomplished group of scientific advisors as we work together to grow Intelligencia AI’s impact on the industry. The company’s rigorous approach to creating foundational data assets and algorithms makes them a unique partner for anyone who believes there is more work to do in order to accelerate new medicines to patients,” shared Ms. Zariffa.